NCT03602235 2025-10-21
High Dose Ascorbic Acid for Plasma Cell Disorders
University of Iowa
Phase 1 Completed
Clinical Trials
13 trialsNCT01125449 2025-05-18
Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease
Situs Cancer Research Center
Phase 2 Withdrawn
NCT02206425 2023-10-31
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
Oncotherapeutics
Phase 1/2 Completed
NCT03964688 2022-04-20
VICAST
Maastricht University Medical Center
Phase 2 Completed
NCT00469209 2020-09-24
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00006021 2016-12-15
Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma
University of Miami
Phase 1/2 Completed
NCT00590603 2014-01-08
AAV
Duke University
Phase 1 Terminated
NCT00317811 2013-11-06
Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00085345 2013-07-10
Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00112879 2013-07-10
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00258245 2013-04-29
Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
Barbara Ann Karmanos Cancer Institute
Phase 1 Completed
NCT00661544 2013-03-04
Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00227682 2012-05-28
Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
OHSU Knight Cancer Institute
Phase 2 Terminated